AbbVie Inc.
AbbVie Unit Gains European Approval for New Cosmetic Neurotoxin
·Consolidated from 1 source
Allergan Aesthetics, a subsidiary of AbbVie, has secured European regulatory approval for Boey, a novel neurotoxin. This treatment is indicated for the temporary improvement of frown lines in adult patients. It marks the introduction of a rapid-onset, short-duration option to the aesthetic market.
AbbVie's aesthetic division, Allergan Aesthetics, has announced a significant regulatory milestone with the approval of Boey (trenibotulinumtoxinE) in Europe.
The new product is designed for the temporary improvement of glabellar lines, commonly known as frown lines, in adult individuals. Reports highlight that Boey is distinguished by its rapid onset of action and short duration, offering a distinct profile compared to existing treatments in the cosmetic neurotoxin market.
This European approval positions Allergan Aesthetics to further compete within the global aesthetic medicine sector. The company aims to provide patients and practitioners with innovative solutions for aesthetic concerns. The introduction of Boey is expected to expand the range of treatment options available for addressing facial wrinkles and lines.
Sources
This recap was generated by consolidating the public headlines below.